| Michael T O'malley, MD | |
|
2401 W Belvedere Ave, Baltimore, MD 21215-5216 | |
| (410) 644-4379 | |
| (410) 644-4325 |
| Full Name | Michael T O'malley |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 19 Years |
| Location | 2401 W Belvedere Ave, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013051499 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | D68447 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sinai Hospital Of Baltimore | Baltimore, MD | Hospital |
| Northwest Hospital Center | Randallstown, MD | Hospital |
| Carroll Hospital Center | Westminster, MD | Hospital |
| Levindale Hebrew Geriatric Center And Hospital | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Drs Hicken Cranley Taylor Pa | 5991776387 | 21 |
| Hct Pathology Services Llc | 2961509856 | 18 |
News Archive
The European League Against Rheumatism has released updated recommendations for the management of RA. According to this latest guidance, treatment with disease-modifying anti-rheumatic drugs should be initiated as soon as a diagnosis of RA is made, with the aim of reaching a target of remission or low disease activity in every patient.
Cognitive remediation, an evidence-based, recovery-oriented behavioral intervention for patients with mental illness, can feasibly be implemented in large systems of care, according to researchers at the New York State Psychiatric Institute and Columbia University Irving Medical Center.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
The way we breathe may affect how well our memories are consolidated (i.e. reinforced and stabilized). If we breathe through the nose rather than the mouth after trying to learn a set of smells, we remember them better, researchers at Karolinska Institutet in Sweden report in The Journal of Neuroscience.
With the disease burden of AIDS, tuberculosis, and malaria expected to make up less than 15 percent of the total disease burden in sub-Saharan Africa (SSA) by 2030, and non-communicable diseases to account for nearly 40 percent of the total in the region, "[a] revision of the approach to research and health care in SSA is therefore urgently needed, but international donors and health communities have generally been slow to respond to the changing environment."
› Verified 8 days ago
| Entity Name | Drs Hicken Cranley Taylor Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154401396 PECOS PAC ID: 5991776387 Enrollment ID: O20040731000367 |
News Archive
The European League Against Rheumatism has released updated recommendations for the management of RA. According to this latest guidance, treatment with disease-modifying anti-rheumatic drugs should be initiated as soon as a diagnosis of RA is made, with the aim of reaching a target of remission or low disease activity in every patient.
Cognitive remediation, an evidence-based, recovery-oriented behavioral intervention for patients with mental illness, can feasibly be implemented in large systems of care, according to researchers at the New York State Psychiatric Institute and Columbia University Irving Medical Center.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
The way we breathe may affect how well our memories are consolidated (i.e. reinforced and stabilized). If we breathe through the nose rather than the mouth after trying to learn a set of smells, we remember them better, researchers at Karolinska Institutet in Sweden report in The Journal of Neuroscience.
With the disease burden of AIDS, tuberculosis, and malaria expected to make up less than 15 percent of the total disease burden in sub-Saharan Africa (SSA) by 2030, and non-communicable diseases to account for nearly 40 percent of the total in the region, "[a] revision of the approach to research and health care in SSA is therefore urgently needed, but international donors and health communities have generally been slow to respond to the changing environment."
› Verified 8 days ago
| Entity Name | Hct Pathology Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598831976 PECOS PAC ID: 2961509856 Enrollment ID: O20070530000295 |
News Archive
The European League Against Rheumatism has released updated recommendations for the management of RA. According to this latest guidance, treatment with disease-modifying anti-rheumatic drugs should be initiated as soon as a diagnosis of RA is made, with the aim of reaching a target of remission or low disease activity in every patient.
Cognitive remediation, an evidence-based, recovery-oriented behavioral intervention for patients with mental illness, can feasibly be implemented in large systems of care, according to researchers at the New York State Psychiatric Institute and Columbia University Irving Medical Center.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
The way we breathe may affect how well our memories are consolidated (i.e. reinforced and stabilized). If we breathe through the nose rather than the mouth after trying to learn a set of smells, we remember them better, researchers at Karolinska Institutet in Sweden report in The Journal of Neuroscience.
With the disease burden of AIDS, tuberculosis, and malaria expected to make up less than 15 percent of the total disease burden in sub-Saharan Africa (SSA) by 2030, and non-communicable diseases to account for nearly 40 percent of the total in the region, "[a] revision of the approach to research and health care in SSA is therefore urgently needed, but international donors and health communities have generally been slow to respond to the changing environment."
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael T O'malley, MD 2330 W Joppa Rd, Suite 100, Lutherville, MD 21093-4609 Ph: (410) 644-4379 | Michael T O'malley, MD 2401 W Belvedere Ave, Baltimore, MD 21215-5216 Ph: (410) 644-4379 |
News Archive
The European League Against Rheumatism has released updated recommendations for the management of RA. According to this latest guidance, treatment with disease-modifying anti-rheumatic drugs should be initiated as soon as a diagnosis of RA is made, with the aim of reaching a target of remission or low disease activity in every patient.
Cognitive remediation, an evidence-based, recovery-oriented behavioral intervention for patients with mental illness, can feasibly be implemented in large systems of care, according to researchers at the New York State Psychiatric Institute and Columbia University Irving Medical Center.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
The way we breathe may affect how well our memories are consolidated (i.e. reinforced and stabilized). If we breathe through the nose rather than the mouth after trying to learn a set of smells, we remember them better, researchers at Karolinska Institutet in Sweden report in The Journal of Neuroscience.
With the disease burden of AIDS, tuberculosis, and malaria expected to make up less than 15 percent of the total disease burden in sub-Saharan Africa (SSA) by 2030, and non-communicable diseases to account for nearly 40 percent of the total in the region, "[a] revision of the approach to research and health care in SSA is therefore urgently needed, but international donors and health communities have generally been slow to respond to the changing environment."
› Verified 8 days ago
Serena Maria Bagnasco, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Baltimore, MD 21224 Phone: 410-955-2660 | |
Dr. Adeboye Oluwaseyi Osunkoya, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 401 N Broadway, Johns Hopkins Pathology , Weinberg Room 2242, Baltimore, MD 21231 Phone: 405-808-5361 | |
Michael Edward Kallen, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 401 N Broadway St, Baltimore, MD 21287 Phone: 410-955-3580 Fax: 410-614-1287 | |
Deyin Xing, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 401 North Broadway, Weinberg 2268, Baltimore, MD 21231 Phone: 410-955-3580 Fax: 410-614-1287 | |
Matthew Grant Gabrielson, Pathology Medicare: Medicare Enrolled Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-3980 | |
Robert A. Palermo, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 6701 N Charles St, Baltimore, MD 21204 Phone: 443-849-2257 Fax: 443-849-3016 |